Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has ...

Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

Medically reviewed by Marla Anderson, MDCancer is as old as humanity, and the history of breast cancer is a fantastic example ...

can make Bendeka less effective rucaparib (Rubraca) — can increase the risk of side effects of Bendeka zafirlukast (Accolate) — can increase the risk of side effects of Bendeka In some cases ...

Nov. 8, 2024 — Scientists believe individuals of the most recently discovered 'hominin' group (the Denisovans) that interbred with modern day humans passed on some of their genes via multiple ...

Nov. 12, 2024 — Researchers have discovered a remarkable new species of sea slug that lives in the deep sea. Nicknamed the 'mystery mollusc,' the nudibranch Bathydevius caudactylus swims through ...

November 12, 2024 • One in four U.S. households experiences a power outage each year. Scientists at Oak Ridge National Laboratory are working on technology they hope will help fix electric grids ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The Biden administration gave Israel 30 days to increase the flow of aid, warning that aid shipments into Gaza in September had reached an alarmingly low level. By Liam Stack and Aaron Boxerman ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...